查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1762315

GLP-1市场，规模，占有率，产业分析报告:各给药途径，各分子类型，所用活性化合物，GLP-1促效剂类别，各目标适应症，各地区，2025年～2034年的市场预测

GLP-1 Market Size, Share, & Industry Analysis Report: By Route of Administration (Oral and Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, and By Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 129 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，GLP-1 市场规模预计到 2034 年将达到 1,339.2 亿美元。本报告深入分析了当前的市场动态，并分析了未来的市场成长。

GLP-1（胰高血糖素样胜肽-1）是一种肠促胰岛素激素，透过促进胰岛素分泌和胰高血糖素的吸收，在葡萄糖代谢中扮演重要角色。在治疗方面，GLP-1 受体激动剂用于治疗第 2 型糖尿病和支持体重管理。 GLP-1 受体激动剂正被纳入 2 型糖尿病和体重管理的治疗，以及肥胖和心血管风险等更广泛的慢性疾病管理框架中。随着GLP-1受体激动剂的临床效用得到越来越广泛的认可，它们正被用作多标靶药物，以适应不断发展的治疗指南。随着GLP-1受体激动剂的临床效用得到越来越广泛的认可，它们正被用作多标靶药物，以适应不断发展的治疗指南。这种不断扩展的效用正推动着医疗保健提供者和患者对以结果为导向的整体护理解决方案的兴趣。

製药公司持续引领技术创新，旨在改善药物输送、便利性和患者依从性。各公司正在增加对下一代製剂和联合疗法的投资，以改善代谢结果，同时减少副作用和给药频率。同时，对个人化治疗方案的日益关注，正在推动针对患者特征的精准GLP-1疗法的开发。总而言之，这些进步显示市场正转向更个人化的长期疾病管理策略。

GLP-1 市场报告重点

按 GLP-1 激动剂药物类型划分，长效 GLP-1 激动剂凭藉其延长的给药间隔、更高的患者依从性和一致的临床疗效，在 2024 年占据市场主导地位。

依给药途径划分，口服 GLP-1 製剂预计在预测期内成长最快。

预计北美将在 2024 年占据最大的收入占有率，这得益于其高发病率、先进的医疗保健系统以及创新疗法的快速应用。

由于生活方式相关的代谢性疾病激增以及医疗保健可近性的不断扩大，预计亚太地区将出现最高增长。

全球主要市场参与者包括阿斯特捷利康、勃林格殷格翰、D&D PharmaTech、礼来、韩美製药、诺和诺德、辉瑞、罗氏、赛诺菲和东方製药。

目录

第1章 简介

第2章 摘要整理

第3章 调查手法

第4章 全球GLP-1市场洞察

  • 材料概述
  • GLP-1市场动态
    • 促进因素和机会
      • 全球第二型糖尿病盛行率上升
      • 肥胖及相关代谢紊乱发病率上升
    • 阻碍因素与课题
      • GLP-1药物的高成本与可负担性课题
  • PESTEL分析
  • GLP-1市场材料趋势
  • 价值链分析

第5章 全球GLP-1市场:各分子类型

  • 主要调查结果
  • 简介
  • 生物製药
  • 小分子

第6章 全球GLP-1市场:所用活性化合物

  • 主要调查结果
  • 简介
  • 度拉鲁肽
  • 利拉鲁肽
  • 奥格列酮
  • 雷托替肽
  • 司美格鲁肽
  • 舒巴替胜肽
  • 替泽帕肽
  • 其他的有效成分

第7章 全球GLP-1市场:GLP-1促效剂类别

  • 主要调查结果
  • 简介
  • 长效型GLP-1促效剂
  • 短效型GLP-1促效剂

第8章 全球GLP-1市场:各给药途径

  • 主要调查结果
  • 简介
  • 口服
  • 非口服

第9章 全球GLP-1市场:各目标适应症

  • 主要调查结果
  • 简介
  • 阿兹海默症
  • 非酒精性脂肪肝炎
  • 肥胖
  • 睡眠呼吸中止症
  • 第二型糖尿病

第10章 全球GLP-1市场:地区

  • 主要调查结果
  • 简介
    • GLP-1市场评估:地区，2020～2034年
  • 北美
    • 各分子类型，2020～2034年
    • 所用活性化合物，2020～2034年
    • GLP-1促效剂类别，2020年～2034年
    • 各给药途径，2020～2034年
    • 各目标适应症，2020～2034年
    • 美国
    • 加拿大
  • 欧洲
    • 各分子类型，2020～2034年
    • 所用活性化合物，2020～2034年
    • GLP-1促效剂类别，2020年～2034年
    • 各给药途径，2020～2034年
    • 各目标适应症，2020～2034年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 各分子类型，2020～2034年
    • 所用活性化合物，2020～2034年
    • GLP-1促效剂类别，2020年～2034年
    • 各给药途径，2020～2034年
    • 各目标适应症，2020～2034年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 各分子类型，2020～2034年
    • 所用活性化合物，2020～2034年
    • GLP-1促效剂类别，2020年～2034年
    • 各给药途径，2020～2034年
    • 各目标适应症，2020～2034年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲
  • 南美
    • 各分子类型，2020～2034年
    • 所用活性化合物，2020～2034年
    • GLP-1促效剂类别，2020年～2034年
    • 各给药途径，2020～2034年
    • 各目标适应症，2020～2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第11章 竞争情形

  • 扩大和收购的分析
    • 扩大
    • 收购
  • 联盟/合作/协定/公开

第12章 企业简介

  • AstraZeneca
  • Boehringer Ingelheim
  • D&D Pharmatech
  • Eli Lilly
  • Hanmi Pharmaceutical
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi
  • Tonghua Dongbao Pharmaceutical
Product Code: PM5759

The GLP-1 Market market size is expected to reach USD 133.92 billion by 2034, according to a new study by Polaris Market Research. The report "GLP-1 Market Share, Size, Trends, Industry Analysis Report: By Route of Administration (Oral and Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

GLP-1 (glucagon-like peptide-1) is an incretin hormone that plays a major role in glucose metabolism by allowing insulin release and incorporating glucagon secretion. Therapeutically, GLP-1 receptor agonists are used to treat type 2 diabetes and support weight management. The growing integration of these therapies into broader chronic disease management frameworks extends their relevance beyond type 2 diabetes to conditions such as obesity and cardiovascular risk. GLP-1 receptor agonists are being adopted as multi-targeted agents that align with evolving treatment guidelines as their clinical benefits become more widely recognized. This expanded utility is promoting greater interest among healthcare providers and patients seeking holistic, outcome-driven care solutions.

The continuous innovation led by pharmaceutical companies aims to improve drug delivery, convenience, and patient compliance. Companies are increasingly investing in next-generation formulations and combination therapies that improve metabolic outcomes with fewer side effects and lower dosing frequency. Alongside this, a growing focus on individualized treatment protocols is encouraging the development of precision-based GLP-1 therapies tailored to patient profiles. These advancements collectively point to a shift in the market toward more personalized and long-term disease control strategies.

GLP-1 Market Report Highlights

In terms of type of GLP-1 agonist drugs, long-acting GLP-1 agonists led the market in 2024, for their extended dosing intervals, better patient compliance, and consistent clinical outcomes.

Based on route of administration, the oral GLP-1 segment is anticipated to grow fastest during the forecast period, driven by increasing preference for needle-free, convenient treatment alternatives.

In 2024, North America accounted for the largest revenue share, supported by high diabetes/obesity rates, cutting-edge healthcare systems, and rapid uptake of innovative therapies.

Asia Pacific is poised for the highest growth, fueled by surging lifestyle-related metabolic disorders and expanding healthcare accessibility.

A few global key market players include AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical.

Polaris Market Research has segmented the market report on the basis of route of administration, type of molecule, active compound used, type of GLP-1 agonist drug, target indication, and region:

By Type of Molecule Outlook (Revenue, USD Billion, 2020-2034)

Biologics

Small Molecules

By Active Compound Used Outlook (Revenue, USD Billion, 2020-2034)

Dulaglutide

Liraglutide

Orforglipron

Retatrutide

Semaglutide

Survodutide

Tirzepatide

Other Active Compounds

By Type of GLP-1 Agonist Drugs Outlook (Revenue, USD Billion, 2020-2034)

Long-acting GLP-1 Agonist

Short-acting GLP-1 Agonist

By Route of Administration Outlook (Revenue, USD Billion, 2020-2034)

Oral

Parenteral

By Target Indication Outlook (Revenue, USD Billion, 2020-2034)

Alzheimer's Disease

Non-Alcoholic Steatohepatitis

Obesity

Sleep Apnea

Type 2 Diabetes

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global GLP-1 Market Insights

  • 4.1. GLP-1 Market - Material Snapshot
  • 4.2. GLP-1 Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of type 2 diabetes globally
      • 4.2.1.2. Increasing rates of obesity and related metabolic disorders
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of GLP-1 drugs and affordability challenges
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. GLP-1 Market Material Trends
  • 4.6. Value Chain Analysis

5. Global GLP-1 Market, by Type of Molecule

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global GLP-1 Market, by Type of Molecule, 2020-2034 (USD Billion)
  • 5.3. Biologics
    • 5.3.1. Global GLP-1 Market, by Biologics, by Region, 2020-2034 (USD Billion)
  • 5.4. Small Molecules
    • 5.4.1. Global GLP-1 Market, by Small Molecules, by Region, 2020-2034 (USD Billion)

6. Global GLP-1 Market, by Active Compound Used

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global GLP-1 Market, by Active Compound Used, 2020-2034 (USD Billion)
  • 6.3. Dulaglutide
    • 6.3.1. Global GLP-1 Market, by Dulaglutide, by Region, 2020-2034 (USD Billion)
  • 6.4. Liraglutide
    • 6.4.1. Global GLP-1 Market, by Liraglutide, by Region, 2020-2034 (USD Billion)
  • 6.5. Orforglipron
    • 6.5.1. Global GLP-1 Market, by Orforglipron, by Region, 2020-2034 (USD Billion)
  • 6.6. Retatrutide
    • 6.6.1. Global GLP-1 Market, by Retatrutide, by Region, 2020-2034 (USD Billion)
  • 6.7. Semaglutide
    • 6.7.1. Global GLP-1 Market, by Semaglutide, by Region, 2020-2034 (USD Billion)
  • 6.8. Survodutide
    • 6.8.1. Global GLP-1 Market, by Survodutide, by Region, 2020-2034 (USD Billion)
  • 6.9. Tirzepatide
    • 6.9.1. Global GLP-1 Market, by Tirzepatide, by Region, 2020-2034 (USD Billion)
  • 6.10. Other Active Compounds
    • 6.10.1. Global GLP-1 Market, by Other Active Compounds, by Region, 2020-2034 (USD Billion)

7. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • 7.3. Long-acting GLP-1 Agonist
    • 7.3.1. Global GLP-1 Market, by Long-acting GLP-1 Agonist, by Region, 2020-2034 (USD Billion)
  • 7.4. Short-acting GLP-1 Agonist
    • 7.4.1. Global GLP-1 Market, by Short-acting GLP-1 Agonist, by Region, 2020-2034 (USD Billion)

8. Global GLP-1 Market, by Route of Administration

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.3. Oral
    • 8.3.1. Global GLP-1 Market, by Oral, by Region, 2020-2034 (USD Billion)
  • 8.4. Parenteral
    • 8.4.1. Global GLP-1 Market, by Parenteral, by Region, 2020-2034 (USD Billion)

9. Global GLP-1 Market, by Target Indication

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • 9.3. ALZHEIMER'S DISEASE
    • 9.3.1. Global GLP-1 Market, by ALZHEIMER'S DISEASE, 2020-2034 (USD Billion)
  • 9.4. Non-Alcoholic Steatohepatitis
    • 9.4.1. Global GLP-1 Market, by Non-Alcoholic Steatohepatitis, 2020-2034 (USD Billion)
  • 9.5. Obesity
    • 9.5.1. Global GLP-1 Market, by Obesity, 2020-2034 (USD Billion)
  • 9.6. Sleep Apnea
    • 9.6.1. Global GLP-1 Market, by Sleep Apnea, 2020-2034 (USD Billion)
  • 9.7. Type 2 Diabetes
    • 9.7.1. Global GLP-1 Market, by Type 2 Diabetes, 2020-2034 (USD Billion)

10. Global GLP-1 Market, by Geography

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. GLP-1 Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 10.3. GLP-1 Market - North America
    • 10.3.1. North America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
    • 10.3.2. North America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
    • 10.3.3. North America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
    • 10.3.4. North America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.3.5. North America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.3.6. GLP-1 Market - US
      • 10.3.6.1. US: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.3.6.2. US: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.3.6.3. US: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.3.6.4. US: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.3.6.5. US: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.3.7. GLP-1 Market - Canada
      • 10.3.7.1. Canada: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.3.7.2. Canada: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.3.7.3. Canada: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.3.7.4. Canada: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.3.7.5. Canada: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • 10.4. GLP-1 Market - Europe
    • 10.4.1. Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
    • 10.4.2. Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
    • 10.4.3. Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
    • 10.4.4. Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.4.5. Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.6. GLP-1 Market - UK
      • 10.4.6.1. UK: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.6.2. UK: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.6.3. UK: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.6.4. UK: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.6.5. UK: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.7. GLP-1 Market - France
      • 10.4.7.1. France: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.7.2. France: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.7.3. France: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.7.4. France: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.7.5. France: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.8. GLP-1 Market - Germany
      • 10.4.8.1. Germany: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.8.2. Germany: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.8.3. Germany: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.8.4. Germany: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.8.5. Germany: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.9. GLP-1 Market - Italy
      • 10.4.9.1. Italy: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.9.2. Italy: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.9.3. Italy: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.9.4. Italy: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.9.5. Italy: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.10. GLP-1 Market - Spain
      • 10.4.10.1. Spain: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.10.2. Spain: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.10.3. Spain: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.10.4. Spain: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.10.5. Spain: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.11. GLP-1 Market - Netherlands
      • 10.4.11.1. Netherlands: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.11.2. Netherlands: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.11.3. Netherlands: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.11.4. Netherlands: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.11.5. Netherlands: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.12. GLP-1 Market - Russia
      • 10.4.12.1. Russia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.12.2. Russia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.12.3. Russia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.12.4. Russia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.12.5. Russia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.13. GLP-1 Market - Rest of Europe
      • 10.4.13.1. Rest of Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.13.2. Rest of Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.13.3. Rest of Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.13.4. Rest of Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.13.5. Rest of Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • 10.5. GLP-1 Market - Asia Pacific
    • 10.5.1. Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
    • 10.5.2. Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
    • 10.5.3. Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
    • 10.5.4. Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.5.5. Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.6. GLP-1 Market - China
      • 10.5.6.1. China: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.6.2. China: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.6.3. China: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.6.4. China: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.6.5. China: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.7. GLP-1 Market - India
      • 10.5.7.1. India: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.7.2. India: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.7.3. India: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.7.4. India: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.7.5. India: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.8. GLP-1 Market - Malaysia
      • 10.5.8.1. Malaysia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.8.2. Malaysia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.8.3. Malaysia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.8.4. Malaysia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.8.5. Malaysia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.9. GLP-1 Market - Japan
      • 10.5.9.1. Japan: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.9.2. Japan: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.9.3. Japan: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.9.4. Japan: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.9.5. Japan: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.10. GLP-1 Market - Indonesia
      • 10.5.10.1. Indonesia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.10.2. Indonesia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.10.3. Indonesia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.10.4. Indonesia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.10.5. Indonesia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.11. GLP-1 Market - South Korea
      • 10.5.11.1. South Korea: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.11.2. South Korea: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.11.3. South Korea: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.11.4. South Korea: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.11.5. South Korea: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.12. GLP-1 Market - Australia
      • 10.5.12.1. Australia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.12.2. Australia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.12.3. Australia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.12.4. Australia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.12.5. Australia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.13. GLP-1 Market - Rest of Asia Pacific
      • 10.5.13.1. Rest of Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.13.2. Rest of Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.13.3. Rest of Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.13.4. Rest of Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.13.5. Rest of Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • 10.6. GLP-1 Market - Middle East & Africa
    • 10.6.1. Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
    • 10.6.2. Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
    • 10.6.3. Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
    • 10.6.4. Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.6.5. Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.6.6. GLP-1 Market - Saudi Arabia
      • 10.6.6.1. Saudi Arabia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.6.6.2. Saudi Arabia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.6.6.3. Saudi Arabia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.6.6.4. Saudi Arabia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.6.5. Saudi Arabia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.6.7. GLP-1 Market - UAE
      • 10.6.7.1. UAE: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.6.7.2. UAE: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.6.7.3. UAE: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.6.7.4. UAE: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.7.5. UAE: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.6.8. GLP-1 Market - Israel
      • 10.6.8.1. Israel: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.6.8.2. Israel: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.6.8.3. Israel: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.6.8.4. Israel: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.8.5. Israel: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.6.9. GLP-1 Market - South Africa
      • 10.6.9.1. South Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.6.9.2. South Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.6.9.3. South Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.6.9.4. South Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.9.5. South Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.6.10. GLP-1 Market - Rest of Middle East & Africa
      • 10.6.10.1. Rest of Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.6.10.2. Rest of Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.6.10.3. Rest of Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.6.10.4. Rest of Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.10.5. Rest of Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • 10.7. GLP-1 Market - Latin America
    • 10.7.1. Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
    • 10.7.2. Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
    • 10.7.3. Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
    • 10.7.4. Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.7.5. Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.7.6. GLP-1 Market - Mexico
      • 10.7.6.1. Mexico: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.7.6.2. Mexico: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.7.6.3. Mexico: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.7.6.4. Mexico: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.6.5. Mexico: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.7.7. GLP-1 Market - Brazil
      • 10.7.7.1. Brazil: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.7.7.2. Brazil: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.7.7.3. Brazil: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.7.7.4. Brazil: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.7.5. Brazil: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.7.8. GLP-1 Market - Argentina
      • 10.7.8.1. Argentina: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.7.8.2. Argentina: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.7.8.3. Argentina: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.7.8.4. Argentina: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.8.5. Argentina: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.7.9. GLP-1 Market - Rest of Latin America
      • 10.7.9.1. Rest of Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.7.9.2. Rest of Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.7.9.3. Rest of Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.7.9.4. Rest of Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.9.5. Rest of Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)

11. Competitive Landscape

  • 11.1. Expansion and Acquisition Analysis
    • 11.1.1. Expansion
    • 11.1.2. Acquisitions
  • 11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

  • 12.1. AstraZeneca
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Benchmarking
    • 12.1.4. Recent Development
  • 12.2. Boehringer Ingelheim
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Benchmarking
    • 12.2.4. Recent Development
  • 12.3. D&D Pharmatech
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Benchmarking
    • 12.3.4. Recent Development
  • 12.4. Eli Lilly
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Benchmarking
    • 12.4.4. Recent Development
  • 12.5. Hanmi Pharmaceutical
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Benchmarking
    • 12.5.4. Recent Development
  • 12.6. Novo Nordisk
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Benchmarking
    • 12.6.4. Recent Development
  • 12.7. Pfizer
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Benchmarking
    • 12.7.4. Recent Development
  • 12.8. Roche
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Benchmarking
    • 12.8.4. Recent Development
  • 12.9. Sanofi
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Benchmarking
    • 12.9.4. Recent Development
  • 12.10. Tonghua Dongbao Pharmaceutical
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Benchmarking
    • 12.10.4. Recent Development

List of Tables:

  • Table 1 Global GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 2 Global GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 3 Global GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 4 Global GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 5 Global GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 6 North America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 7 North America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 8 North America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 9 North America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 10 North America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 11 US: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 12 US: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 13 US: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 14 US: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 15 US: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 16 Canada: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 17 Canada: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 18 Canada: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 19 Canada: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 20 Canada: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 21 Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 22 Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 23 Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 24 Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 25 Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 26 UK: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 27 UK: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 28 UK: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 29 UK: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 30 UK: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 31 France: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 32 France: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 33 France: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 34 France: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 35 France: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 36 Germany: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 37 Germany: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 38 Germany: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 39 Germany: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 40 Germany: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 41 Italy: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 42 Italy: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 43 Italy: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 44 Italy: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 45 Italy: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 46 Spain: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 47 Spain: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 48 Spain: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 49 Spain: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 50 Spain: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 51 Netherlands: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 52 Netherlands: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 53 Netherlands: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 54 Netherlands: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 55 Netherlands: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 56 Russia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 57 Russia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 58 Russia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 59 Russia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 60 Russia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 61 Rest of Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 62 Rest of Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 63 Rest of Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 64 Rest of Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 65 Rest of Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 66 Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 67 Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 68 Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 69 Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 70 Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 71 China: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 72 China: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 73 China: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 74 China: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 75 China: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 76 India: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 77 India: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 78 India: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 79 India: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 80 India: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 81 Malaysia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 82 Malaysia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 83 Malaysia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 84 Malaysia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 85 Malaysia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 86 Japan: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 87 Japan: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 88 Japan: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 89 Japan: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 90 Japan: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 91 Indonesia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 92 Indonesia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 93 Indonesia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 94 Indonesia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 95 Indonesia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 96 South Korea: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 97 South Korea: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 98 South Korea: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 99 South Korea: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 100 South Korea: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 101 Australia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 102 Australia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 103 Australia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 104 Australia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 105 Australia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 106 Rest of Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 107 Rest of Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 108 Rest of Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 109 Rest of Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 110 Rest of Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 111 Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 112 Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 113 Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 114 Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 115 Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 116 Saudi Arabia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 117 Saudi Arabia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 118 Saudi Arabia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 119 Saudi Arabia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 120 Saudi Arabia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 121 UAE: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 122 UAE: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 123 UAE: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 124 UAE: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 125 UAE: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 126 Israel: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 127 Israel: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 128 Israel: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 129 Israel: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 130 Israel: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 131 South Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 132 South Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 133 South Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 134 South Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 135 South Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 136 Rest of Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 137 Rest of Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 138 Rest of Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 139 Rest of Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 140 Rest of Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 141 Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 142 Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 143 Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 144 Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 145 Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 146 Mexico: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 147 Mexico: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 148 Mexico: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 149 Mexico: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 150 Mexico: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 151 Brazil: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 152 Brazil: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 153 Brazil: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 154 Brazil: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 155 Brazil: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 156 Argentina: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 157 Argentina: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 158 Argentina: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 159 Argentina: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 160 Argentina: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 161 Rest of Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 162 Rest of Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 163 Rest of Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 164 Rest of Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 165 Rest of Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global GLP-1 Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market By Type of Molecule
  • Figure 7. Global GLP-1 Market, By Type of Molecule, 2024 & 2034 (USD Billion)
  • Figure 8. Market By Active Compound Used
  • Figure 9. Global GLP-1 Market, By Active Compound Used, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Type of GLP-1 Agonist Drugs
  • Figure 11. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2024 & 2034 (USD Billion)
  • Figure 12. Market by Route of Administration
  • Figure 13. Global GLP-1 Market, by Route of Administration, 2024 & 2034 (USD Billion)
  • Figure 14. Market by Target Indication
  • Figure 15. Global GLP-1 Market, by Target Indication, 2024 & 2034 (USD Billion)